Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS

NCT04517253 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04517253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Terminated
Start date
October 27, 2020
Completion date
November 28, 2024
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aicardi goutieres syndrome, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome, nakajo-nishimura syndrome, sting-associated vasculopathy with onset in infancy